NICE recommends thalidomide for patients with multiple myeloma

07/27/2011 | Bloomberg

U.K.'s National Institute for Health and Clinical Excellence has recommended the use of Celgene's thalidomide in combination with two other treatments as first-line treatment for patients with multiple myeloma who cannot tolerate high-dose chemotherapy and stem cell transplants. NICE said patients who cannot use thalidomide can use Velcade as an alternative drug.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC